Novel histone acetyltransferase p300 bromodomain inhibitor as well as medicinal composition and application thereof

By designing a new p300 bromodomain inhibitor, the problem of insufficient biological activity and selectivity of p300/CBP bromodomain inhibitors in the prior art is solved, and effective inhibition of histone acetyltransferase p300 and a variety of tumor cells are achieved. The significant inhibitory effect of the disease demonstrates excellent bioavailability and metabolic stability, and promotes the development of anti-tumor drugs.

CN118930520APending Publication Date: 2024-11-12FUDAN UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310523481.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing p300/CBP bromodomain inhibitors, such as CCS1477, have problems with low cell membrane permeability and short in vivo half-life, which limits their biological activity and clinical application potential, and targets inhibitors of p300/CBP bromodomain. There are few types and studies, and it is difficult to meet the needs of multiple tumor treatments.

Method used

A series of novel p300 bromodomain inhibitors are designed with inhibitory activity and selectivity better than CCS1477. By synthesizing specific compounds and their derivatives, their structure is optimized to improve bioavailability and metabolic stability, for inhibiting histones. The activity of acetyltransferase p300 significantly inhibits the growth of various tumor cells.

Benefits of technology

The novel compound significantly inhibits the activity of p300 at the molecular and cellular level, which is better than the clinical drug CCS1477, and has a strong tumor growth inhibition effect, especially in the prostate cancer cell model, which shows tumor decline effect and good metabolic stability. and safety, with broad potential for anti-tumor drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930520A_ABST
    Figure CN118930520A_ABST
Patent Text Reader

Abstract

The invention discloses a p300 bromodomain inhibitor and a derivative thereof. The p300 bromodomain inhibitor has a structure as shown in a formula I: # imgabs0 #. The invention also discloses a pharmaceutical composition containing the compound and the derivative thereof and application of the pharmaceutical composition as the p300 bromodomain inhibitor. The compound and the derivative thereof can significantly inhibit the activity of histone acetyltransferase p300, have strong proliferation inhibition activity on multiple myeloma cells OPM-2, prostate cancer cells 22RV1 and the like, have good metabolic stability, safety and drug-likeness, and can be used as candidate molecules for development of antitumor drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The patent of this invention belongs to the field of synthetic medicinal chemistry, and specifically relates to a novel p300 bromodomain inhibitor, a pharmaceutical composition and an application thereof. Background Art

[0002] Acetylation and deacetylation of histone lysine residues are reversible post-translational modifications that play a vital role in regulating gene expression and are the focus of epigenetic research. The histone acetylation process is regulated by three factors: histone acetyltransferase (HAT), histone deacetylase (HDAC) and bromodomain-containing protein (BCP).

[0003] Acetylated proteins can carry different genetic information and regulate gene expression. Acetylated lysine residues (KAc) can be specifically recognized by bromodomains. Bromodomain-containing proteins can recognize KAc of histones through their bromodomains, read the genetic information carried by post-translationally modified histones, and thus regulate gene expression. Therefore, bromodomains are currently very attractive targets for regulating gene expression, and the study of their inhibitors is an important direction for the development of tumor drugs.

[0004] The p300 / CBP family, composed of the highly homologous adenovirus E1A-related 300kDa protein (adenoviral E1A binding protein of 300kDa, p300) and the CREB binding protein (CBP), is one of the main members of the HAT family. Due to their structural homology and functional similarities, they are often collectively referred to as p300 / CBP.

[0005] Histone acetyltransferase p300 / CBP plays a vital role in epigenetic regulation. It can participate in the acetylation process of histones in organisms and affect the balance of histone acetylation and deacetylation. p300 / CBP with bromodomain can specifically recognize KAc and read the genetic information carried by post-translationally modified histones. Therefore, it can play a role in epigenetic regulation of gene expression and is essential for maintaining body homeostasis.

[0006] Studies have shown that abnormalities in the function of p300 / CBP bromodomains are closely related to the occurrence and development of a variety of tumors, such as prostate cancer, multiple myeloma, acute myeloid leukemia and breast cancer. Targeting the p300 / CBP bromodomains has gradually become a new method for treating cancer. Currently, the reported p300 / CBP bromodomain inhibitors have very few structural types and numbers, and only two candidate compounds have entered the clinical research stage. One is FT-7051, developed by Forma Theraputics, which is currently in the clinical phase I research stage for the treatment of metastatic castration-resistant prostate cancer. The other is CCS1477, developed by Cellcentric, which is currently in the clinical phase I / II research stage for the treatment of acute myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma and metastatic castration-resistant prostate cancer. CCS1477 has certain defects. First, CCS1477 has low cell permeability, and second, CCS1477 has a short in vitro and in vivo half-life. Therefore, based on the biological functions of p300 / CBP bromodomains and the biological activities of their inhibitors, the discovery of p300 / CBP bromodomain inhibitors with stronger activity, higher selectivity and better drug-like properties has gradually become a research hotspot for major pharmaceutical companies and research institutes. This is of great significance to the study of p300 / CBP biological functions and the development of epigenetic drugs. Summary of the invention

[0007] The present invention designs and synthesizes a series of novel p300 bromodomain inhibitors, provides compounds having a general formula (I) structure or derivatives such as pharmaceutically acceptable salts thereof as p300 small molecule inhibitors, and conducts biological evaluation on them, and finds that the obtained substances have better inhibitory activity at the molecular level and the cellular level than CCS1477 and have good drug-like properties and can be used as p300 bromodomain inhibitors.

[0008] The results of biological experiments show that the compounds and their derivatives of the present invention have better inhibitory effects than the clinical compound CCS1477 at the molecular and cellular levels as p300 bromodomain inhibitors. In the prostate cancer cell 22RV1 animal model, the optimal compound exhibits a strong tumor growth inhibitory effect and can achieve tumor regression effects at high dosages. It can also significantly reduce the expression level of c-Myc in cells and mice. At the same time, these compounds or their derivatives have high selectivity and good bioavailability as inhibitors, and have great potential for the development of anti-tumor drugs.

[0009] In a first aspect, the present invention provides a compound or a derivative thereof (including, for example, a deuterated substance, a salt, an isomer, a crystalline form or a solvate thereof), characterized in that the compound has a structure as shown in the following formula I:

[0010]

[0011] R1, R2, R3 and R4 are each independently selected from hydrogen, deuterium, halogen, haloalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy or cyano;

[0012] R5 is selected from substituted or unsubstituted 3-10 membered saturated or unsaturated alicyclic or alicyclic heterocyclic or alicyclic;

[0013] R6 is selected from hydrogen or halogen;

[0014] R7 is selected from substituted or unsubstituted aromatic rings, aromatic heterocycles or aromatic rings;

[0015] X is selected from a covalent bond, -CH2- or -CH2CH2-;

[0016] Y1 and Y2 are each independently selected from CH or N.

[0017] In a second aspect, the present invention provides a pharmaceutical composition comprising: (1) the compound according to the first aspect of the present invention or a deuterated substance, salt, isomer, crystal form or solvate thereof; and (2) a pharmaceutically acceptable carrier and / or excipient.

[0018] In a third aspect, the present invention provides use of the compound described in the first aspect of the present invention or a deuterated substance, salt, isomer, crystal form or solvate thereof as a p300 bromodomain inhibitor.

[0019] Biological experiments have confirmed that the novel p300 bromodomain inhibitors provided by the present invention can significantly inhibit the activity of histone acetyltransferase p300, and the compounds of the present invention have excellent inhibitory effects on a variety of tumor cells including prostate cancer cells, leukemia cells, breast cancer cells, and multiple myeloma cells (such as OPM-2), and the inhibitory effect is even better than the target clinical drug CCS1477. The compounds of the present invention and their derivatives also have good metabolic stability, safety and drug-like properties, and can be used as candidate molecules for the development of anti-tumor drugs. Therefore, the compounds of the present invention and their derivatives have broad application prospects in the preparation of p300 inhibitors, as well as in the prevention and / or treatment of tumors, myeloid hematopoietic stem cell diseases, and in the regulation of regulatory T cells. DETAILED DESCRIPTION

[0020] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention will be described more clearly and completely in conjunction with specific implementation methods below. However, the embodiments described herein are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0021] Definitions of terms used in the present invention: Unless otherwise stated, the initial definitions provided for groups or terms in this document apply to the groups or terms throughout the specification; for terms that are not specifically defined in this document, the meaning that a person skilled in the art can give them should be given based on the disclosure and context.

[0022] The "alicyclic ring" mentioned herein refers to a saturated or unsaturated cyclic hydrocarbon fragment or group, and the "alicyclic heterocycle" refers to a saturated or unsaturated cyclic fragment or group containing heteroatoms (including but not limited to nitrogen, oxygen, and sulfur).

[0023] The term "pharmaceutically acceptable" as used herein means that a carrier, vehicle, diluent, excipient, and / or salt formed is generally chemically or physically compatible with other ingredients constituting a pharmaceutical dosage form and physiologically compatible with the receptor.

[0024] "Salt" mentioned herein refers to acidic and / or basic salts formed by a compound or its stereoisomer with inorganic and / or organic acids and / or bases, also including zwitterionic salts (inner salts), and also including quaternary ammonium salts, such as alkylammonium salts. These salts can be directly obtained in the final separation and purification of the compound. It can also be obtained by mixing the compound, or its isomer, with a certain amount of acid or base appropriately (e.g., equivalent). These salts may form a precipitate in the solution and be collected by filtering, or be recovered after the solvent is evaporated, or be obtained by freeze drying after reaction in an aqueous medium.

[0025] In the present invention, the salt may be a hydrochloride, sulfate, citrate, benzenesulfonate, hydrobromide, hydrofluoride, phosphate, acetate, propionate, succinate, oxalate, malate, succinate, fumarate, maleate, tartrate or trifluoroacetate of the compound.

[0026] The "solvate" mentioned herein refers to a solvate formed by the compound of the present invention and a solvent, wherein the solvent includes but is not limited to: water, ethanol, methanol, isopropanol, propylene glycol, tetrahydrofuran or dichloromethane.

[0027] The "deuterated compound" mentioned herein refers to a compound obtained by replacing one or more hydrogen atoms in the compound of the present invention with deuterium.

[0028] As described above, the present invention provides, in the first aspect, a compound or a deuterated substance, salt, isomer, crystalline form or solvate thereof, characterized in that the compound has a structure as shown in the following formula I:

[0029]

[0030] R1, R2, R3 and R4 are each independently selected from hydrogen, deuterium, halogen, haloalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy or cyano;

[0031] R5 is selected from substituted or unsubstituted 3-10 membered saturated or unsaturated alicyclic or alicyclic heterocyclic or alicyclic;

[0032] R6 is selected from hydrogen or halogen;

[0033] R7 is selected from substituted or unsubstituted aromatic rings, aromatic heterocycles or aromatic rings;

[0034] X is selected from a covalent bond, -CH2- or -CH2CH2-;

[0035] Y1 and Y2 are each independently selected from CH or N.

[0036] It is also preferred or further preferred that R1, R2, R3 and R4 are independently selected from C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, C 3-12 A substituent in cycloalkyl, halogen, difluoromethyl, trifluoromethyl or cyano.

[0037] It is also preferred or further preferred that the substituted or unsubstituted 3-10 membered saturated or unsaturated alicyclic or alicyclic heterocyclic or alicyclic substituents of R5 are one or more selected from C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, hydroxy, C 1-6 Substituents in alkyl ester groups or halogens.

[0038] It is also preferred or further preferred that R6 is selected from hydrogen or fluorine.

[0039] It is also preferred or further preferred that the substituents on the substituted aromatic ring or aromatic ring of R7 are one or more selected from C 1-6 Alkyl, C 3-6Cycloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyloxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, hydroxyl, C 1-6 Alkyl ester, halogen, cyano, nitro, amino, C 1-6 Alkylamino or C 1-6 Substituents in the alkylacylamino group.

[0040] It is also preferred or further preferred that R5 is selected from It is also preferred or further preferred that R7 is selected from

[0041]

[0042] It is also preferred or further preferred that the compound is one of the following compounds:

[0043]

[0044]

[0045]

[0046]

[0047] The second aspect of the present invention provides a pharmaceutical composition, which comprises: (1) the compound described in the first aspect of the present invention or the deuterated form, salt, isomer, crystal form or solvate of the compound (as an active ingredient); and (2) a pharmaceutically acceptable carrier and / or excipient (as an excipient).

[0048] The third aspect of the present invention provides use of the compound described in the first aspect of the present invention or the deuterated substance, salt, isomer, crystal form or solvate thereof as a p300 bromodomain inhibitor.

[0049] In addition or further preferably, the p300 bromodomain inhibitor is used as a drug for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem cells, and regulating regulatory T cells.

[0050] More preferably, the tumor is selected from one or more of hematological malignancies, gastric cancer, intestinal cancer, cervical cancer, bladder cancer, laryngeal cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma or multiple myeloma.

[0051] Preparation Example: Synthesis of (2S,4R)-4-fluoro-5-oxopyrrolidine-2-carboxylic acid and (2S,4S)-4-fluoro-5-oxopyrrolidine-2-carboxylic acid

[0052]

[0053] At room temperature, sodium periodate (3 equiv) and ruthenium trichloride (0.2 equiv) were dissolved in a solution of EA:H2O=1:2, and then commercially available raw materials N-BOC-trans-4-fluoro-L-proline methyl ester (1 equiv) or N-BOC-cis-4-fluoro-L-proline methyl ester (1 equiv) were added to the solution, reacted for 5 hours, 100 mL of EA was added thereto, and the mixture was washed with saturated sodium bicarbonate solution, saturated sodium dithionite solution and saturated sodium chloride solution, respectively, and the organic phase was collected, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. Under ice bath conditions, a 4M solution of hydrogen chloride dioxane was added dropwise to the crude product, reacted at room temperature for 3 hours, and the reaction solution was spin-dried to obtain a crude product. The crude product was dissolved in a solution of THF:MeOH:H2O=1:1:3, lithium hydroxide (1.5 equiv) was added thereto, reacted for 8 hours, and the reaction solution was spin-dried and freeze-dried to obtain a crude product, which can be directly used in the next step.

[0054] Example

[0055] The above contents of the present invention are further described in detail below by way of examples. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of protection claimed by the present invention.

[0056] Example 1: Synthesis of 5-(2-((2S,4S)-1-(3,4-difluorophenyl)-4-fluoro-5-oxopyrrolidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one

[0057] Step 1: Synthesis of intermediate 1-2:

[0058]

[0059] The starting material 1-1 (5 g, 22.7 mmol), trans-4-methoxycyclohexyl-1-amine (2.9 g, 22.7 mmol), and potassium carbonate (4.7 g, 34.1 mmol) were dissolved in 70 mL of acetonitrile and reacted overnight at 75°C. After the reaction was completed, the mixture was cooled, filtered, and the filter cake was washed with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain intermediate 1-2 (7.0 g, yield 93.6%), which was directly used in the next step without further purification.

[0060] Step 2: Synthesis of intermediate 1-3:

[0061]

[0062] The intermediate 1-2 (7 g, 21.3 mmol) obtained in the previous step was dissolved in 150 mL of 1:1 tetrahydrofuran and aqueous solution, 10 mL of ammonia water was added dropwise to the solution, followed by sodium dithionite (18.5 g, 106.3 mmol), and the mixture was reacted at room temperature for 2 hours. After the reaction was completed, 50 mL of water was added, and the mixture was extracted with ethyl acetate (2*100 mL), the organic phases were combined, washed with saturated sodium chloride solution (1*100 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (petroleum ether: ethyl acetate = 1:1) to obtain the product intermediate 1-3 (4.5 g, yield 70.7%).

[0063] Step 3: Synthesis of intermediate 1-4:

[0064]

[0065] The intermediate 1-3 (1 g, 3.3 mmol) obtained in the previous step, (2S, 4S)-4-fluoro-5-oxopyrrolidine-2-carboxylic acid (491.6 mg, 3.3 mmol), HATU (CAS NO: 148893-10-1, 1.9 g, 5.01 mmol) and N, N-diisopropylethylamine (863.9 mg, 6.7 mmol) were dissolved in 10 mL of N, N-dimethylformamide and reacted at room temperature for 3 hours. After the reaction was completed, 50 mL of water was added, and ethyl acetate was extracted (2*50 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product (1.5 g) was dissolved in 10 mL of acetic acid and reacted at 75°C overnight. After the reaction was completed, the mixture was cooled and dried by rotation, 50 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate (2*50 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 30:1) to obtain intermediate 1-4 (820 mg, yield 62.7%).

[0066] Step 4: Synthesis of intermediate 1-5:

[0067]

[0068] The intermediate 1-4 obtained in the previous step (200 mg, 0.49 mmol), 3,4-difluorophenylboronic acid (231 mg, 1.5 mmol), copper acetate monohydrate (117 mg, 0.59 mmol), and pyridine (309 mg, 3.9 mmol) were dissolved in 10 mL of dichloromethane and reacted at room temperature for 3 hours. After the reaction was completed, the reaction solution was dried, 50 mL of water was added, and ethyl acetate was extracted (1*50 mL). The organic phases were combined, washed with saturated sodium chloride solution (1*50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was subjected to column chromatography (dichloromethane: methanol = 50:1) to obtain intermediate 1-5 (190 mg, yield 74.6%).

[0069] Step 5: Synthesis of 5-(2-((2S,4S)-1-(3,4-difluorophenyl)-4-fluoro-5-oxopyrrolidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one:

[0070]

[0071] Intermediate 1-5 (20 mg, 38.3 μmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylpyridine)-2(1H)-one (11.5 mg, 45.9 μmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (2.8 mg, 3.8 umol), potassium carbonate (7.9 mg, 57.4 μmol) were dissolved in 4 mL of 3:1 dioxane and water, replaced with nitrogen three times, and reacted at 85°C for 4 hours. After the reaction was completed, cooled, 25 mL of water was added, extracted with ethyl acetate (2*25 mL), the organic phases were combined, washed with saturated sodium chloride solution (1*25 mL), dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (dichloromethane: methanol = 20:1) to obtain the target compound 1 (15.1 mg, yield 69.4%).

[0072] The following Examples 2 to 16 were synthesized by the method described in Example 1, or by using corresponding intermediates in a similar manner to Example 1.

[0073]

[0074]

[0075]

[0076] The target compounds synthesized in Examples 1 to 16 and their molecular structures and 1 H NMR spectrum.

[0077]

[0078]

[0079]

[0080]

[0081] Example 17: Synthesis of 5-(2-((2S,4S)-4-fluoro-1-(3-fluoro-4-methoxyphenyl)-5-oxopyrrolidin-2-yl)-1-((trans)4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one

[0082] Step 1: Synthesis of intermediate 17-1:

[0083]

[0084] Intermediate 1-4 (300 mg, 731.2 μmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylpyridine)-2(1H)-one (218.6 mg, 877.4 μmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (53.3 mg, 73.1 μmol), potassium carbonate (151.6 mg, 1.1 mmol) were dissolved in 12 mL of 3:1 dioxane and water, replaced with nitrogen three times, and reacted at 85°C for 4 hours. After the reaction was completed, cooled, 50 mL of water was added, extracted with ethyl acetate (2*50 mL), the organic phases were combined, washed with saturated sodium chloride solution (1*50 mL), dried over anhydrous sodium sulfate, concentrated, and the crude product was separated by column chromatography (dichloromethane: methanol = 10:1) to obtain intermediate 17-1 (206 mg, yield 62.3%).

[0085] Step 2: Synthesis of 5-(2-((2S,4S)-4-fluoro-1-(3-fluoro-4-methoxyphenyl)-5-oxopyrrolidin-2-yl)-1-((trans)4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one

[0086]

[0087] The intermediate 17-1 obtained in the previous step (20 mg, 44.2 μmol), 3-fluoro-4-methoxyphenylboronic acid (22.5 mg, 132.6 μmol), copper acetate monohydrate (10.6 mg, 53 μmol), and pyridine (28 mg, 353.6 μmol) were dissolved in 3 mL of dichloromethane and reacted at room temperature for 3 hours. After the reaction was completed, the reaction solution was dried, 25 mL of water was added, and ethyl acetate (1*25 mL) was extracted, the organic phases were combined, washed with saturated sodium chloride solution (1*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was purified by column chromatography (dichloromethane: methanol = 20:1) to obtain the target compound 17 (17.3 mg, yield 69.3%).

[0088] The following Examples 18 to 24 were synthesized by the method described in Example 17, or were synthesized in a similar manner to Example 17 using corresponding intermediates.

[0089]

[0090]

[0091] The target compounds synthesized in Examples 17 to 24 and their molecular structures and mass spectra (MS).

[0092]

[0093]

[0094] Example 25: Synthesis of 5-(2-((2S,4R)-1-(3,4-difluorophenyl)-4-fluoro-5-oxopyrrolidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one

[0095] Step 1: Synthesis of intermediate 25-1:

[0096]

[0097] Dissolve intermediate 1-3 (1 g, 3.3 mmol), (2S, 4R)-4-fluoro-5-oxopyrrolidine-2-carboxylic acid (491.6 mg, 3.3 mmol), HATU (CAS NO: 148893-10-1, 1.9 g, 5.01 mmol), N,N-diisopropylethylamine (863.9 mg, 6.7 mmol) in 10 mL of N,N-dimethylformamide and react at room temperature for 3 hours. After the reaction is complete, add 50 mL of water, extract with ethyl acetate (2*50 mL), combine the organic phases, wash with saturated sodium chloride solution (2*50 mL), dry with anhydrous sodium sulfate, concentrate, and dissolve the obtained crude product (1.5 g) in 10 mL of acetic acid and react at 75°C overnight. After the reaction was completed, the mixture was cooled and dried by spin drying. 50 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate (2*50 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 30:1) to obtain intermediate 25-1 (820 mg, yield 62.7%).

[0098] Step 2: Synthesis of intermediate 25-2:

[0099]

[0100] The intermediate 25-1 obtained in the previous step (200 mg, 0.49 mmol), 3,4-difluorophenylboronic acid (231 mg, 1.5 mmol), copper acetate monohydrate (117 mg, 0.59 mmol), and pyridine (309 mg, 3.9 mmol) were dissolved in 10 mL of dichloromethane and reacted at room temperature for 3 hours. After the reaction was completed, the reaction solution was dried, 50 mL of water was added, and ethyl acetate (1*50 mL) was extracted, the organic phases were combined, washed with saturated sodium chloride solution (1*50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was subjected to column chromatography (dichloromethane: methanol = 50:1) to obtain intermediate 25-2 (190 mg, yield 74.6%).

[0101] Step 3: Synthesis of 5-(2-((2S,4S)-1-(3,4-difluorophenyl)-4-fluoro-5-oxopyrrolidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1,3-dimethylpyridin-2(1H)-one:

[0102]

[0103] The intermediate 25-2 (20 mg, 38.3 μmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylpyridine)-2(1H)-one (11.5 mg, 45.9 μmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (2.8 mg, 3.8 umol), potassium carbonate (7.9 mg, 57.4 μmol) were dissolved in 4 mL of 3:1 dioxane and water, replaced with nitrogen three times, and reacted at 85°C for 4 hours. After the reaction was completed, the mixture was cooled, 25 mL of water was added, and ethyl acetate (2*25 mL) was extracted. The organic phases were combined, washed with saturated sodium chloride solution (1*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 20:1) to obtain the target compound 25 (15.1 mg, yield 69.4%).

[0104] The following Examples 26 to 30 were synthesized by the method described in Example 25, or were synthesized in a similar manner to Example 25 using corresponding intermediates.

[0105]

[0106] The target compounds synthesized in Examples 25 to 30 and their molecular structures and mass spectra (MS).

[0107]

[0108]

[0109] Example 31: Synthesis of 3-chloro-5-(2-((S)-1-(3,4-difluorophenyl)-4-oxoazetidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1-methylpyridin-2(1H)-one

[0110] Step 1: Synthesis of intermediate 31-1:

[0111]

[0112] Intermediate 1-3 (100 mg, 334.2 μmol), (S)-4-oxoazetidine-2-carboxylic acid (38.5 mg, 334.2 μmol), HATU (CAS NO: 148893-10-1, 190.5 mg, 501.3 μmol), N,N-diisopropylethylamine (86.39 mg, 668.4 μmol) were dissolved in 5 mL of N,N-dimethylformamide and reacted at room temperature for 3 hours. After the reaction was completed, 25 mL of water was added, and ethyl acetate was extracted (2*25 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product (150 mg) was dissolved in 5 mL of acetic acid and reacted at 75°C overnight. After the reaction was completed, the mixture was cooled and dried by rotation, 20 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate (2*25 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 30:1) to obtain intermediate 31-1 (88.5 mg, yield 70.0%).

[0113] Step 2: Synthesis of intermediate 31-2:

[0114]

[0115] The intermediate 31-1 obtained above (50 mg, 132.2 μmol), 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylpyridine)-2(1H)-one (39.5 mg, 158.6 μmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (9.6 mg, 13.2 μmol), and potassium carbonate (27.4 mg, 198.3 μmol) were dissolved in 4 mL of 3:1 dioxane and water, replaced with nitrogen three times, and reacted at 85°C for 4 hours. After the reaction was completed, the mixture was cooled and 25 mL of water was added. The mixture was extracted with ethyl acetate (2*25 mL). The organic phases were combined, washed with saturated sodium chloride solution (1*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 10:1) to obtain intermediate 31-2 (30.3 mg, yield 54.5%).

[0116] Step 3: Synthesis of 3-chloro-5-(2-((S)-1-(3,4-difluorophenyl)-4-oxoazetidin-2-yl)-1-((trans)-4-methoxycyclohexyl)-1H-benzo[d]imidazol-5-yl)-1-methylpyridin-2(1H)-one

[0117]

[0118] The intermediate 31-2 obtained in the previous step (30 mg, 71.3 μmol), 3,4-difluorophenylboronic acid (33.8 mg, 214.0 μmol), copper acetate monohydrate (15.7 mg, 78.5 μmol), pyridine (45.1 mg, 570.7 μmol) were dissolved in 3 mL of dichloromethane and reacted at room temperature for 3 hours. After the reaction was completed, the reaction solution was dried, 25 mL of water was added, and ethyl acetate (1*25 mL) was extracted, the organic phases were combined, washed with saturated sodium chloride solution (1*25 mL), dried over anhydrous sodium sulfate, concentrated, and the crude product was subjected to column chromatography (dichloromethane: methanol = 20:1) to obtain the target compound 31 (25.2 mg, yield 66.3%).

[0119] The following Examples 32 to 38 and Examples 47 to 53 were synthesized by the method described in Example 31, or were synthesized in a similar manner to Example 31 using corresponding intermediates.

[0120]

[0121]

[0122] The target compounds synthesized in Examples 31 to 38 and Examples 47 to 53 and their substructures and 1 HNMR spectrum.

[0123]

[0124]

[0125]

[0126]

[0127] Example 39: Synthesis of (trans)-4-(5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-1H-benzo[d]imidazol-1-yl)cyclohexyl acetate

[0128] Step 1: Synthesis of intermediate 39-1:

[0129]

[0130] The starting material 1-1 (5 g, 22.7 mmol), trans-4-aminocyclohexane-1-ol (2.6 g, 22.7 mmol), and potassium carbonate (4.7 g, 34.1 mmol) were dissolved in 70 mL of acetonitrile and reacted overnight at 75°C. After the reaction was completed, the mixture was cooled, filtered, and the filter cake was washed with ethyl acetate, dried over anhydrous sodium sulfate, and concentrated to obtain intermediate 1-2 (6.8 g, yield 94.9%), which was directly used in the next step without further purification.

[0131] Step 2: Synthesis of intermediate 39-2:

[0132]

[0133] The intermediate 39-1 (200 mg, 634.6 μmol) obtained in the previous step was dissolved in 10 mL of dichloromethane, triethylamine (128.4 mg, 27 mmol) was added thereto, and acetyl chloride (74.7 mg, 951.9 μmol) was added dropwise to the reaction system under ice bath conditions, and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, the reaction system was dried, and the crude product was separated by column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain the product intermediate 39-2 (103.2 mg, yield 45.5%)

[0134] Step 3: Synthesis of intermediate 39-3:

[0135]

[0136] The intermediate 39-2 (103.2 mg, 288.9 μmol) obtained in the previous step was dissolved in 20 mL of 1:1 tetrahydrofuran and aqueous solution, 200 μL of ammonia water was added dropwise to the solution, followed by sodium dithionite (402.4 mg, 2.3 mmol), and the reaction was carried out at room temperature for 1 hour. After the reaction was completed, 30 mL of water was added, and the organic phase was extracted with ethyl acetate (1*50 mL), and washed with saturated sodium chloride solution (1*100 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (petroleum ether: ethyl acetate = 2:1) to obtain the product intermediate 39-3 (60.1 mg, yield 63.6%).

[0137] Step 4: Synthesis of intermediate 39-4:

[0138]

[0139] The intermediate 39-3 (60 mg, 183.4 μmol) obtained in the previous step, (S)-5-oxopyrrolidine-2-carboxylic acid (23.7 mg, 183.4 mmol), HATU (CAS NO: 148893-10-1, 104.5 mg, 275 μmol), N,N-diisopropylethylamine (47.4 mg, 366.7 μmol) were dissolved in 3 mL of N,N-dimethylformamide and reacted at room temperature for 3 hours. After the reaction was completed, 25 mL of water was added, and ethyl acetate was extracted (2*25 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product (90 mg) was dissolved in 5 mL of acetic acid and reacted at 75°C overnight. After the reaction was completed, the mixture was cooled and dried by spin drying. 25 mL of saturated sodium bicarbonate solution was added, and the mixture was extracted with ethyl acetate (2*50 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*50 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 30:1) to obtain intermediate 39-4 (40 mg, yield 51.9%).

[0140] Step 5: Synthesis of intermediate 39-5:

[0141]

[0142] The intermediate 39-4 obtained in the previous step (40 mg, 95.2 μmol), 3,4-difluorophenylboronic acid (45.1 mg, 285.5 μmol), copper acetate monohydrate (20.9 mg, 104.7 μmol), and pyridine (60.2 mg, 761.4 μmol) were dissolved in 5 mL of dichloromethane and reacted at room temperature for 3 hours. After the reaction was completed, the reaction solution was dried, 25 mL of water was added, ethyl acetate was extracted (1*25 mL), washed with saturated sodium chloride solution (2*25 mL), dried over anhydrous sodium sulfate, concentrated, and the crude product was subjected to column chromatography (dichloromethane: methanol = 50:1) to obtain intermediate 39-5 (40.1 mg, yield 79.2%).

[0143] Step 6: Synthesis of (trans)-4-(5-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-1H-benzo[d]imidazol-1-yl)cyclohexyl acetate:

[0144]

[0145] The intermediate 39-5 obtained in the previous step (40 mg, 79.3 μmol), 3-chloro-1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-ylpyridine)-2(1H)-one (25.7 mg, 95.2 μmol), 1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride (5.8 mg, 7.9 μmol), potassium carbonate (16.4 mg, 119.0 μmol) were dissolved in 4 mL of 3:1 dioxane and water, replaced with nitrogen three times, and reacted at 85°C for 4 hours. After the reaction was completed, the mixture was cooled, 25 mL of water was added, and ethyl acetate (2*25 mL) was extracted. The organic phases were combined, washed with saturated sodium chloride solution (1*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (dichloromethane: methanol = 20:1) to obtain the target compound 39 (29.4 mg, yield 62.3%).

[0146] Example 40: Synthesis of 3-chloro-5-(2-((S)-1-(3,4-difluorophenyl)-5-oxopyrrolidin-2-yl)-1-((trans)-4-(methoxy-d3)cyclohexyl)-1H-benzo[d]imidazol-5-yl)-1-methylpyridin-2(1H)-one

[0147] Step 1: Synthesis of intermediate 40-1:

[0148]

[0149] The intermediate 39-1 (100 mg, 317.3 μmol) was dissolved in 5 mL of N, N-dimethylformamide, and sodium hydride (60%) (63.5 mg, 1.59 mmol) was slowly added thereto under ice bath conditions, and the reaction was carried out for 10 minutes. Then, deuterated iodomethane (55.2 mg, 380.8 μmol) was added dropwise to the reaction system. After the addition was complete, the reaction was carried out at room temperature for 2 hours. After the reaction was completed, 25 mL of water was added, and ethyl acetate was extracted (2*25 mL). The organic phases were combined, washed with saturated sodium chloride solution (2*25 mL), dried over anhydrous sodium sulfate, and concentrated. The crude product was separated by column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain the intermediate 40-1 (56.3 mg, yield 53.4%).

[0150] Step 2-5 was carried out by referring to Step 3-6 in Example 39 to obtain the target compound 40.

[0151] The following Examples 41 to 46 and Examples 54 to 63 were synthesized by the method described in Example 39 or 40, or by a method similar to Example 31 using corresponding intermediates.

[0152]

[0153]

[0154] The target compounds synthesized in Examples 39 to 46 and Examples 54 to 63 and their molecular structures and 1 HNMR spectrum.

[0155]

[0156]

[0157]

[0158]

[0159] Comparative Example 1 (CCS1477)

[0160]

[0161] The compound CCS1477 used was purchased from MCE.

[0162] Test Example 1: In vitro inhibitory activity test of compounds on histone acetyltransferase p300

[0163] AlphaLISA technology is used to detect the inhibitory activity of compounds on the bromodomain of p300 protein. AlphaLISA uses microbeads as donors and acceptors to detect biological molecules. If the detection target is present in the sample, the donor microbeads and the acceptor microbeads will approach each other due to the specific recognition of the antibody, thereby stimulating the cascade amplified chemiluminescent reaction on the acceptor microbeads, and finally transmitting the signal to europium to generate a signal.

[0164] Prepare 1x detection buffer before use. Dilute the compound with DMSO to the desired concentration of the reaction, and then transfer 5 μL of the compound from the source plate to the assay plate (OptiPlate-384). Prepare protein and peptide solutions in 1x detection buffer. Add 2.5 μL of protein solution and 2.5 μL of peptide solution to each well. Centrifuge the assay plate at 1000 rpm for 1 minute and incubate at room temperature for 20 minutes. Prepare acceptor microbead and donor microbead solutions in 1x detection buffer. Add 10 μL of acceptor bead solution to each well of the assay plate, and incubate the assay plate at room temperature for 1 hour. Add 10 μL of donor bead solution to each well of the assay plate, and incubate the assay plate at room temperature for 30 minutes. Read the signal using Tecan's Alpha mode. Analyze the data using graphPad prism. The experimental results are shown in Table 1.

[0165] Table 1: In vitro inhibitory activity of compounds on p300

[0166]

[0167]

[0168] ++++: represents IC 50 <30nM

[0169] +++: represents 30nM≤IC 50 <100nM

[0170] ++: represents 100nM≤IC 50 <1μM

[0171] From the above results, it can be seen that the compounds of the present invention can strongly inhibit the activity of histone acetyltransferase p300, and the inhibitory activity of some compounds is better than that of the clinical drug CCS1477 under investigation for this target, and is worthy of further development.

[0172] Test example 2: CCK8 method to detect sensitive cell proliferation inhibition experiment

[0173] The compounds of the present invention were used to test the inhibitory effect on tumor cell proliferation. The compounds of the present invention were used to test the cell growth inhibitory activity of the p300 / CBP inhibition sensitive cell lines obtained in the previous work (OPM-2 cells were purchased from the German Microbiological Collection (DSMZ), and 22RV1 cells were purchased from the Cobham Cell Bank). Cells in the logarithmic growth phase were plated at 2.5×10 3 The concentration of cells was inoculated into a 96-well plate, and the gradient dilution of the compound was added after 24 hours. After inoculation, the flow culture was carried out for 5 days, and then 10 μL of CCK-8 reagent (Cell Counting Kit-8 cell counting reagent) was added to each well and cultured at 37°C for 2-6 hours. The absorbance of each well at a wavelength of 450 nm was read using an ELISA reader and analyzed using SoftMax Pro 5.4.1 software. IC was calculated using the four-parameter method using GraphPad Prism 5 statistical software 50 The experimental results are shown in Table 2.

[0174] Table 2: Antiproliferation activity of compounds on tumor cells

[0175]

[0176]

[0177] From the above results, it can be seen that the compounds of the present invention exhibited excellent anti-proliferation effects on multiple myeloma cells OPM-2 and prostate cancer cells, and can be used as candidate p300 bromodomain inhibitors for the treatment of related cancers.

[0178] Test Example 3: Pharmacokinetic Evaluation

[0179] Animal Information

[0180] Species / strain: ICR (CD-1) mice; Sex / number: male; Body weight (g): male (25-30 g).

[0181] Feeding method: standard sawtooth diet, no restriction on drinking water, fasting started 12h before administration and remained fasting for 2h after administration.

[0182] Housing environment: The animal room environment was controlled (target conditions: temperature 18 to 29°C, relative humidity 30 to 70%. Temperature and relative humidity were monitored daily. An electronic time-controlled lighting system was used to provide a 12-hour light / 12-hour dark cycle.

[0183] Dosing Information

[0184]

[0185] Sample collection

[0186] ICR mice were orally administered with 10 mg / kg of the test compound in a dosing volume of 10 mL / kg. Blood was collected from the orbital venous plexus at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 8 h, and 24 h after administration into heparinized EP tubes and temporarily placed on crushed ice.

[0187] Sample processing and analysis

[0188] Centrifuge at 8000rpm for 5min, transfer 15μL of the upper plasma to a 96-well plate. Add 150μL of methanol:acetonitrile (v / v=1:1) (containing 20ng / mL tolbutamide) to 15μL of plasma, oscillate for 3min, centrifuge at 4500rpm for 5min, and take 100μL of supernatant to a 2mL deep-well plate. Add 100μL of diluent (pure water), oscillate for 3min, and centrifuge at 4500rpm for 5min. Transfer 180μL of supernatant to the sample injection plate, analyze the content of the compound in the supernatant sample by LC-MS / MS, and calculate various pharmacokinetic parameters using WinNonlin software. The pharmacokinetic parameters of the test compounds are shown in Table 3.

[0189] Table 3: PK properties of some inventive compounds in mice

[0190]

[0191] The experimental results show that the compound of the present invention has good oral absorption exposure and high C max and AUC, and has a longer half-life T 1 / 2These data indicate that the compounds of the present invention have the potential to become orally effective anti-tumor drugs.

[0192] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A compound or a deuterated substance, salt, isomer, crystalline form or solvate thereof, characterized in that: The compound has the structure shown in the following formula I: in, R1, R2, R3 and R4 are each independently selected from hydrogen, deuterium, halogen, haloalkyl, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy or cyano; R5 is selected from substituted or unsubstituted 3-10 membered saturated or unsaturated alicyclic or alicyclic heterocyclic or alicyclic; R6 is selected from hydrogen or halogen; R7 is selected from substituted or unsubstituted aromatic rings, aromatic heterocycles or aromatic rings; X is selected from a covalent bond, -CH2- or -CH2CH2-; Y1 and Y2 are each independently selected from CH or N.

2. The compound according to claim 1, or the deuterated substance, salt, isomer, crystal form or solvate thereof, characterized in that: R1, R2, R3 and R4 are independently selected from C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, C 3-12 A substituent in cycloalkyl, halogen, difluoromethyl, trifluoromethyl or cyano.

3. The compound according to claim 1, or the deuterated substance, salt, isomer, crystal form or solvate thereof, characterized in that: The substituted or unsubstituted 3-10 membered saturated or unsaturated alicyclic or alicyclic heterocyclic or alicyclic substituents of R5 are one or more selected from C 1-10 Alkyl, C 1-10 Alkoxy, C 2-10 Alkenyl, C 2-10 Alkynyl, halogen substituted C 1-10 Alkyl, C 3-12 Cycloalkyl, C 3-12 Cycloalkoxy, hydroxy, C 1-6 Substituents in alkyl ester groups or halogens.

4. The compound according to claim 1, or a deuterated substance, salt, isomer, crystal form or solvate thereof, characterized in that: R6 is selected from hydrogen or fluorine.

5. The compound according to claim 1, or the deuterated substance, salt, isomer, crystal form or solvate thereof, characterized in that: The substituents on the substituted aromatic ring or aromatic ring of R7 are one or more selected from C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyloxy, halogenated C 1-6 Alkyl, halogenated C 1-6 Alkoxy, hydroxyl, C 1-6 Alkyl ester, halogen, cyano, nitro, amino, C 1-6 Alkylamino or C 1-6 Substituents in the alkylacylamino group.

6. The compound according to claim 1, or the deuterated substance, salt, isomer, crystal form or solvate thereof, characterized in that: R5 is selected from and / or R7 is selected from 7. The compound according to claim 1, or a deuterated substance, salt, isomer, crystal form or solvate thereof, characterized in that: The compound is one of the following compounds:

8. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises: (1) the compound according to any one of claims 1 to 7, or a deuterated form, salt, isomer, crystal form or solvate thereof; and (2) Pharmaceutically acceptable carriers and / or excipients.

9. Use of the compound according to any one of claims 1 to 7, or the deuterated substance, salt, isomer, crystal form or solvate thereof, and the pharmaceutical composition according to claim 8 in the preparation of a p300 bromodomain inhibitor drug; Preferably, the p300 bromodomain inhibitor is used as a drug for preventing and / or treating tumors, malignant diseases of myeloid hematopoietic stem cells, and regulating regulatory T cells; More preferably, the tumor is selected from one or more of hematological malignancies, gastric cancer, intestinal cancer, cervical cancer, bladder cancer, laryngeal cancer, liver cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer, lymphoma or multiple myeloma.